Please enable Javascript
bexmarilimab
FDA, Finnish Medicines Agency Approve Initiation of Phase I/II Study of Bexmarilimab
Kerri Fitzgerald
Acute Myeloid Leukemia
|
February 2, 2023
The FDA and Finnish Medicines Agency cleared the investigational new drug application for bexmarilimab.
Read More
FDA OKs Study of Bexmarilimab in AML/MDS/CML
Leah Lawrence
Chronic Myeloid Leukemia
|
February 2, 2023
The phase I/II study will assess the safety and tolerability of the drug.
Read More
Advertisement
Advertisement
Advertisement